According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
Several other research firms also recently weighed in on ADMS. Mizuho reissued a buy rating and set a $37.00 price target on shares of Revance Therapeutics in a research report on Wednesday, April 24th. HC Wainwright set a $55.00 price target on Acer Therapeutics and gave the stock a buy rating in a research report on Tuesday, May 28th. Finally, ValuEngine downgraded Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $18.91.
Adamas Pharmaceuticals stock opened at $6.00 on Wednesday. The company has a quick ratio of 6.86, a current ratio of 7.03 and a debt-to-equity ratio of 2.00. The business’s fifty day moving average is $5.27. Adamas Pharmaceuticals has a fifty-two week low of $4.20 and a fifty-two week high of $29.49.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.05. The company had revenue of $11.67 million during the quarter, compared to the consensus estimate of $12.78 million. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. On average, research analysts anticipate that Adamas Pharmaceuticals will post -3.77 EPS for the current year.
Several hedge funds have recently bought and sold shares of the company. Healthcare Value Capital LLC acquired a new stake in shares of Adamas Pharmaceuticals during the first quarter worth $711,000. Granite Investment Partners LLC acquired a new stake in shares of Adamas Pharmaceuticals during the first quarter worth $304,000. Fosun International Ltd boosted its holdings in shares of Adamas Pharmaceuticals by 13.7% during the first quarter. Fosun International Ltd now owns 223,959 shares of the specialty pharmaceutical company’s stock worth $1,610,000 after purchasing an additional 27,000 shares during the last quarter. PNC Financial Services Group Inc. acquired a new stake in shares of Adamas Pharmaceuticals during the first quarter worth $43,000. Finally, Bainco International Investors boosted its holdings in shares of Adamas Pharmaceuticals by 71.4% during the first quarter. Bainco International Investors now owns 24,000 shares of the specialty pharmaceutical company’s stock worth $171,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 76.68% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Further Reading: Blue-Chip Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.